

## Confirmed Speakers

### Confirmed Speakers

#### **Metal-Catalyzed C–H Bond Functionalizations for Sustainable Synthesis**

Prof. Lutz ACKERMANN  
(GEORG-AUGUST UNIVERSITY GOETTINGEN, Goettingen, Germany)

#### **Chemical Probes for Epigenetics**

Dr Mark BUNNAGE  
(PFIZER, Boston, United States)

#### **Novel Metabotropic Glutamate Receptor 4 (mGluR4) Allosteric Potentiators for the Treatment of Parkinson's Disease**

Dr Sylvain CELANIRE  
(ADDEX PHARMACEUTICALS, Geneva, Switzerland)

#### **A few of my Favorite Rings: Catalysis Inspired by Lactones and Lactams**

Prof. Vy M. DONG  
(UNIVERSITY OF TORONTO, Toronto, Canada)

#### **Tofacitinib (CP-690,550): Discovery of a Potent and Selective JAK Inhibitor**

Dr Mark FLANAGAN  
(PFIZER, Connecticut, United States)

#### **Antibody Directed Cytotoxics**

Prof. John FLYGARE  
(GENENTECH, California, United States)

#### **From Homer to Hedgehog: Chemistry, Biological Investigations and Medical Perspectives of Cyclopamine**

Prof. Athanassios GIANNIS  
(UNIVERSITY OF LEIPZIG, Leipzig, Germany)

#### **Bicyclic Peptides with Tailored Binding Specificities for Therapeutic Application**

Prof. Christian HEINIS  
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

#### **Regioselective Reactions on a Chiral Substrate Controlled by the Configuration of a Chiral Catalyst**

Prof. Henri KAGAN  
(UNIVERSITY PARIS-SUD 11, ORSAY Cedex, France)

#### **Discovery and Development of Novel Antimalarials**

Dr Rodney KIP GUY  
(ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States)

#### **Target Synthesis Directed Methodology Development**

Prof. Dawei MA  
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China)

#### **Minor Enantiomer Recycling – A Strategy for Improving Enantioselectivity**

Prof. Christina MOBERG  
(KTH SCHOOL OF CHEMICAL SCIENCE AND ENGINEERING, Stockholm, Sweden)

#### **Magical Power of d-Block Transition Metals—Pd-Catalyzed Cross-Coupling and Zr-Catalyzed Asymmetric carboalumination of Alkenes (ZACA)**

Prof. Ei-ichi NEGISHI  
(PURDUE UNIVERSITY, West Lafayette, United States)

#### **Maitotoxin. An Inspiration for Synthesis**

## Confirmed Speakers

Prof. K.C. NICOLAOU  
(THE SCRIPPS RESEARCH INSTITUTE & UNIVERSITY OF CALIFORNIA, Houston, United States)

### **Small Molecules Inhibitors of the WNT Signalling Pathway with Potential Applications in Oncology**

Dr Alessandro PADOVA  
(SIENA BIOTECH, Siena, Italy)

### **Design Strategy for Preparation of Drug-like Polyheterocycles with Privileged Substructures for Discovery of Specific Small Molecule Modulators**

Prof. Seung Bum PARK  
(SEOUL NATIONAL UNIVERSITY, Seoul, Korea, South)

### **Synthesis of Marine Polyketides as Promising Anticancer Agents**

Prof. Ian PATERSON  
(CAMBRIDGE UNIVERSITY, Cambridge, United Kingdom)

### **GPR119: Knowledge Based Lead Identification**

Dr Sherrie L. PIETRANICO-COLE  
(ROCHE, NUTLEY NJ, United States)

### **A Step Closer to Hepatitis C Remedy: TMC435, an HCV Protease Inhibitor in Advanced Clinical Trial**

Dr Pierre RABOISSON  
(JANSSEN PHARMACEUTICAL COMPANIES, Mechelen, Belgium)

### **The Many Uses of Noncovalent Mass Spectrometry in Early-stage Drug Discovery**

Dr Jean-Paul RENAUD  
(NOVALIX, Ostwald, France)

### **The Resurgence of Covalent Drugs**

Dr Juswinder SINGH  
(AVILA THERAPEUTICS, United States)

### **Lessons in Chemoselectivity: Total Synthesis of Polyphenolic Natural Products**

Prof. Scott SNYDER  
(COLUMBIA UNIVERSITY, New York, United States)

### **Asymmetric Synthesis of Bioactive Molecules**

Prof. Mikiko SODEOKA  
(RIKEN, Hirosawa, Japan)

### **Biochemical Efficiency, a Metrics for an Optimal Molecular Mechanism of Action**

Dr David SWINNEY  
(IRND3, Mountain View, United States)

### **Drug Discovery by Programmed Self-Assembly**

Prof. Nicolas WINSSINGER  
(UNIVERSITY OF STRASBOURG, Geneva, Switzerland)

### **Bromodomains a New Class of Epigenetic Targets Ripe for Small Molecule Drug Discovery**

Dr Jason WITHERINGTON  
(GLAXOSMITHKLINE R&D, Stevenage, United Kingdom)

### **Validation of N-Myristoyltransferase as a Drug Target**

Prof. Paul WYATT  
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

### **Accelerated C-H Activation Reactions: Enantioselectivity and Positional Selectivity**

## Confirmed Speakers

Prof Jin-Quan YU  
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)

## Selected Oral Communications

### Small Molecule Inhibitors of the Neuropilin-1 VEGF-A Interaction

Dr Philip FALLON  
(DOMAINEX, Saffron Walden, United Kingdom)

### Halogen Bonding in Protein–ligand Interactions

Mr Leo HARDEGGER  
(ETH ZURICH, Zürich, Switzerland)

### The Chemical Biology Consortium- and Experimental Therapeutics Program

Dr Sanjay MALHOTRA  
(NATIONAL CANCER INSTITUTE, Frederick, United States)

### Adventures in Medicinal Chemistry and Knowledge Capture

Dr Alexander MAYWEG  
(F. HOFFMANN-LA ROCHE LTD, BASEL, Switzerland)

### Identification of Bisaryloxy Azetidine Urea Derivatives as Fatty Acid Amide Hydrolase Inhibitors

Dr Hans MEISSNER  
(VERNALIS, Winnersh, United Kingdom)

### Identification of Leads from the Tres Cantos Antimalarial Set: Cyclopropyl Carboxamides Show Good Oral Bioavailability and Efficacy In Malarial Animal Models

Mrs Maria Lourdes RUEDA-BENEDE  
(GLAXOSMITHKLINE, Tres Cantos, Spain)

### Highly Efficient Catalytic System for C-H Activation: A Novel and Practical Synthesis of Angiotensin II Receptor Blockers

Dr Masahiko SEKI  
(MITSUBISHI TANABE PHARMA CORPORATION, Fukuoka, Japan)

### The Grandisine Alkaloids as Selective $\mu$ -Opioid Receptor Agonists; When is a Natural Product not a Natural Product?

Prof. Richard TAYLOR  
(UNIVERSITY OF YORK, York, United Kingdom)

### Exploring the Rigid Mono- and Diamine Chemical Space

Dr Dmytro VOLOCHNYUK  
(ENAMINE LTD., Kiev, Ukraine)

### Lead identification of a new class of P2Y<sub>12</sub> inhibitors "From a low active and insoluble HTS hit to soluble and active lead compounds"

Mr Fredrik ZETTERBERG  
(ASTRAZENECA, Gothenburg, Sweden)

### The Chemistry of Targeting Protein-Protein Interactions: Thinking Outside of the Box

Dr Giovanna ZINZALLA  
(CANCER RESEARCH UK - THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON, London, United Kingdom)